Status:
COMPLETED
Special Drug Use Investigation of EYLEA for Myopic Choroidal Neovascularization
Lead Sponsor:
Bayer
Collaborating Sponsors:
Regeneron Pharmaceuticals
Conditions:
Choroidal Neovascularization
Eligibility:
All Genders
Brief Summary
The objectives of this study are to investigate the safety and effectiveness of EYLEA.
Detailed Description
This is a prospective, non-interventional, multi center post-authorization safety study that includes patients with a diagnosis of myopic choroidal neovascularization. The investigator will have made ...
Eligibility Criteria
Inclusion
- Patients who start EYLEA treatment for mCNV(myopic choroidal neovascularization).
Exclusion
- Patients who have already received EYLEA treatment.
Key Trial Info
Start Date :
December 5 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 22 2018
Estimated Enrollment :
353 Patients enrolled
Trial Details
Trial ID
NCT02260687
Start Date
December 5 2014
End Date
August 22 2018
Last Update
September 19 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Multiple Locations, Japan